[Molecular basis of arsenic action in promyelocytic leukemia cells].
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001151:Arsenic / Q000627:therapeutic use*; D002453:Cell Cycle / Q000235:genetics; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009154:Mutation; D009363:Neoplasm Proteins / Q000378:metabolism; D009504:Neutrophils / Q000473:pathology; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D014157:Transcription Factors / Q000378:metabolism; D014212:Tretinoin / Q000627:therapeutic use; D025521:Tumor Suppressor Proteins
D009363:Neoplasm Proteins; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D018168:Receptors, Retinoic Acid; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human; D014212:Tretinoin; D001151:Arsenic
Molekularne podstawy działania arszeniku w komórkach białaczki promielocytowej.